Severity score system for progressive myelopathy: development and validation of a new clinical scale.

Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas
R M CastilhosLaura B Jardim

Abstract

Progressive myelopathies can be secondary to inborn errors of metabolism (IEM) such as mucopolysaccharidosis, mucolipidosis, and adrenomyeloneuropathy. The available scale, Japanese Orthopaedic Association (JOA) score, was validated only for degenerative vertebral diseases. Our objective is to propose and validate a new scale addressing progressive myelopathies and to present validating data for JOA in these diseases. A new scale, Severity Score System for Progressive Myelopathy (SSPROM), covering motor disability, sphincter dysfunction, spasticity, and sensory losses. Inter- and intra-rater reliabilities were measured. External validation was tested by applying JOA, the Expanded Disability Status Scale (EDSS), the Barthel index, and the Osame Motor Disability Score. Thirty-eight patients, 17 with adrenomyeloneuropathy, 3 with mucopolysaccharidosis I, 3 with mucopolysaccharidosis IV, 2 with mucopolysaccharidosis VI, 2 with mucolipidosis, and 11 with human T-cell lymphotropic virus type-1 (HTLV-1)-associated myelopathy participated in the study. The mean ± SD SSPROM and JOA scores were 74.6 ± 11.4 and 12.4 ± 2.3, respectively. Construct validity for SSPROM (JOA: r = 0.84, P < 0.0001; EDSS: r = -0.83, P < 0.0001; Barthel: r = 0.5...Continue Reading

References

Feb 1, 1987·Physical Therapy·R W Bohannon, M B Smith
Apr 1, 1995·Journal of the Neurological Sciences·A Q AraújoM J Andrada-Serpa
Jul 1, 1997·Journal of Neurology, Neurosurgery, and Psychiatry·B M van GeelP G Barth
Aug 1, 1997·Brain : a Journal of Neurology·H W Moser
Apr 24, 2002·Journal of Neurology, Neurosurgery, and Psychiatry·I S J MerkiesUNKNOWN Inflammatory Neuropathy Cause and Treatment (INCAT) group
Feb 12, 2005·Journal of Strength and Conditioning Research·Joseph P Weir
Feb 9, 2008·Journal of the Neurological Sciences·Mariana Garcia CrodaJorge Casseb
Jul 12, 2008·Journal of Inherited Metabolic Disease·S Al SawafB Hoffmann
Sep 17, 2008·American Journal of Medical Genetics. Part a·Maria-Veronica Munoz-RojasRoberto Giugliani
Dec 29, 2009·Molecular Genetics and Metabolism·María Verónica Muñoz-RojasRoberto Giugliani

❮ Previous
Next ❯

Citations

Dec 12, 2018·Brain : a Journal of Neurology·Irene C HuffnagelMarc Engelen
Nov 14, 2019·Journal of Neurology·Wouter J C van BallegoijFrank D Verbraak
Dec 14, 2019·BMJ Supportive & Palliative Care·Colleen PawliukHarold Hal Siden
Aug 9, 2020·Frontiers in Physiology·Wouter J C van BallegoijMarc Engelen
Feb 23, 2020·Journal of Inherited Metabolic Disease·Stephanie I W van de StadtMarc Engelen
Apr 30, 2015·Metabolic Brain Disease·Clarissa Troller HabekostLaura Bannach Jardim
Jan 30, 2018·The British Journal of Radiology·Elif BulutBurce Ozgen
Oct 14, 2020·Annals of Clinical and Translational Neurology·Wouter J C van BallegoijMarc Engelen
Mar 31, 2021·Annals of Clinical and Translational Neurology·Wouter J C van BallegoijFrank D Verbraak
Aug 31, 2021·NeuroImage. Clinical·Stephanie I W van de StadtMarc Engelen

❮ Previous
Next ❯

Software Mentioned

SSPROM

Related Concepts

Related Feeds

Adrenoleukodystrophy

Adrenoleukodystrophy (ALD), the most frequent peroxisomal disorder, is an X-linked disorder caused by a defect in the metabolism of long chain fatty acids leading to demyelination, neurodegeneration, and death. Here is the latest research.